Puberty, Precocious
Conditions
Keywords
Early/precocious puberty, advanced puberty, national observatory, private medicine, feasibility
Brief summary
The age of puberty has fluctuated throughout history. Recent data shows an increase in the age of onset of puberty signs, in the United States but also in Europe. A recent Public Health France study published in 2018 reports an increase in the incidence of precocious puberty with geographical heterogeneity. The consequences of these appearances include the early onset of menarche, short adult height and the psychological impact. Due to a lack of studies and additional data, the reasons for this development are difficult to understand. Among current hypotheses, the entanglement with the evolution of our environment is at the forefront: the action of environmental endocrine disruptors and nutritional factors could play a role in the process of early appearance of pubertal signs. The establishment of a national observatory for early and advanced puberty in collaboration with pediatric endocrinologists (on the front line) would allow a reliable and precise field approach, capable of supplementing epidemiological data, which are currently insufficient. The investigators hypothesize that the establishment of an observatory of pubertal advances (early puberty and advanced puberty) in private medicine is possible, with inclusion of at least 75% of eligible patients, and collection of at least 80% of data.
Interventions
None listed
Sponsors
Hospices Civils de Lyon
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 11 Years
Healthy volunteers
Yes
Inclusion criteria
Precocious puberty group (PP) : * Suspected precocious puberty (girl aged \< 8 years or boy aged \< 9 years when the first signs of development\* appear) * Suspected precocious puberty (girl aged \< 8 years or boy aged \< 9 years when the first signs of development\* appear) Advanced puberty group (AP) : * Suspected advanced puberty (girl aged ≥ 8 and \< 10 years or boy aged ≥ 9 and \< 11 years when the first signs of development\* appear) * First consultation with the investigator (pediatric endocrinologist). Control group : * Boy or girl without signs of pubertal development (Tanner 1); * Matched to the PP group on sex and age (+/- 1 year); * Consultation with the same investigator over the same period (same quarter) as a patient in the PP group
Exclusion criteria
All groups * Consultation with the same investigator over the same period (same quarter) as a patient in the PP group * Family not speaking French, language barrier.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of recruited patients with at least 80% of the main data collected | Up to 48 month | Number of recruited patients with at least 80% of the main data collected (weight, height, BMI, pubertal stage, date of onset of pubertal signs, questionnaires). |
| Missing data rate | Up to 48 month | Missing data rate less than 10% for pubertal stage. |
| At least 75% of patients included | Up to 48 month | At least 75% of patients included compared to the number of eligible patients. |
Countries
France
Contacts
Primary ContactEmillie Doye, MD
Backup ContactTiphanie GINHOUX
Outcome results
None listed